Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26482497 | 0.81 | EGLN1 (0.36) | — | |
| SCHEMBL17348186 | 0.80 | ADORA2A (0.41) | ADORA2AADORA2BALDH1A1BTK | |
| SCHEMBL13106281 | 0.73 | CHRM4 (0.38) | ADORA2AADORA2BBTK | |
| SCHEMBL13106286 | 0.73 | L3MBTL1 (0.43) | ADORA2AADORA2B | |
| SCHEMBL10151107 | 0.73 | ADORA2A (0.60) | ADORA2AADORA2B | |
| SCHEMBL22357763 | 0.73 | LMNA (0.37) | ALDH1A1BTK | |
| SCHEMBL15341789 | 0.73 | RAB9A (0.37) | ALDH1A1 | |
| SCHEMBL13106332 | 0.72 | L3MBTL1 (0.42) | ADORA2AADORA2BALDH1A1 | |
| SCHEMBL13106328 | 0.72 | ADORA2A (0.35) | ADORA2AADORA2BBTK | |
| SCHEMBL26741175 | 0.71 | ADORA2A (0.40) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| US-20120277258-A1 | Chemical Compounds | LEO OSPREY LIMITED (JE) | 2012-11-01 | — | — | US | disclosed |
| US-8114885-B2 | Pazopanib hydrochloride and synthesis, chemical intermediates, and dosage forms thereof; anticancer; colon cancer, breast cancer | GLAXOSMITHKLINE LLC (US) | 2012-02-14 | — | — | US | disclosed |
| US-7858626-B2 | Pyrimidineamines as angiogenesis modulators | GLAXOSMITHKLINE LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100105712-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100010022-A1 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20070292513-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-12-20 | — | — | US | disclosed |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-11-22 | — | — | US | disclosed |
| US-20070208023-A1 | Cancer Treatment Method | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-06 | — | — | US | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010022-A1 | CANCER TREATMENT METHOD | TP53, TYMP, TOP2A | DHFR 22/4885ADORA2A 1110/4885ADORA2B 1349/4885 |
| US-20070208023-A1 | Cancer Treatment Method | TP53, TYMP, TOP2A | DHFR 22/4885ADORA2A 1110/4885ADORA2B 1349/4885 |
| US-20070015756-A1 | Chemical compounds | KDR, FLT4, FLT1 | DHFR 15/4885ADORA2A 482/4885ADORA2B 704/4885 |
| US-20100105712-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | DHFR 15/4885ADORA2A 482/4885ADORA2B 704/4885 |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | DHFR 1867/4885ADORA2A 1442/4885ADORA2B 371/4885 |
| US-20120277258-A1 | Chemical Compounds | KDR, FLT4, FLT1 | DHFR 15/4885ADORA2A 482/4885ADORA2B 704/4885 |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | DHFR 15/4885ADORA2A 482/4885ADORA2B 704/4885 |
| US-20070292513-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | DHFR 15/4885ADORA2A 482/4885ADORA2B 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.